Your browser doesn't support javascript.
loading
Development and Validation of a Tool to Identify Patients Diagnosed With Castration-Resistant Prostate Cancer.
Candelieri-Surette, Danielle; Hung, Anna; Lynch, Julie A; Pridgen, Kathryn M; Agiri, Fatai Y; Li, Weiyan; Aggarwal, Himani; Anglin-Foote, Tori; Lee, Kyung Min; Perez, Cristina; Reed, Shelby; DuVall, Scott L; Wong, Yu-Ning; Alba, Patrick R.
Afiliação
  • Candelieri-Surette D; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT.
  • Hung A; Durham VA Medical Center, Durham, NC.
  • Lynch JA; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
  • Pridgen KM; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC.
  • Agiri FY; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT.
  • Li W; Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT.
  • Aggarwal H; Department of Nursing & Health Sciences, University of Massachusetts, Boston, Boston, MA.
  • Anglin-Foote T; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT.
  • Lee KM; Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT.
  • Perez C; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT.
  • Reed S; AstraZenca Pharmaceuticals, LP, Gaithersburg, MD.
  • DuVall SL; Merck & Co, Inc, Rahway, NJ.
  • Wong YN; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT.
  • Alba PR; Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT.
JCO Clin Cancer Inform ; 7: e2300085, 2023 Sep.
Article em En | MEDLINE | ID: mdl-37862671
PURPOSE: Several novel therapies for castration-resistant prostate cancer (CRPC) have been approved with randomized phase III studies with continuing observational research either planned or ongoing. Accurately identifying patients with CRPC in electronic health care data is critical for quality observational research, resource allocation, and quality improvement. Previous work in this area has relied on either structured laboratory results and medication data or natural language processing (NLP) methods. However, a computable phenotype using both structured data and NLP identifies these patients with more accuracy. METHODS: The Corporate Data Warehouse (CDW) of the Veterans Health Administration (VHA) was used to collect PCa diagnoses, prostate-specific antigen test results, and information regarding patient characteristics and medication use. The final system used for validation and subsequent analysis combined the NLP system and an algorithm of structured laboratory and medication data to identify patients as being diagnosed with CRPC. Patients with both a documented diagnosis of CRPC and a documented diagnosis of metastatic PCa were classified as having mCRPC by this system. RESULTS: Among 1.2 million veterans with PCa, the International Classification of Diseases (ICD)-10 diagnosis code for CRPC (Z19.2) identifies 3,791 patients from 2016 when the code was created until 2022, compared with the combined algorithm which identifies 14,103, 10,312 more than ICD-10 codes alone, from 2016 to 2022. The combined algorithm showed a sensitivity of 97.9% and a specificity of 99.2%. CONCLUSION: ICD-10 codes proved to be insufficient for capturing CRPC in the VHA CDW data. Using both structured and unstructured data identified more than double the number of patients compared with ICD-10 codes alone. Application of this combined approach drastically improved identification of real-world patients and enables high-quality observational research in mCRPC.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração Limite: Humans / Male Idioma: En Revista: JCO Clin Cancer Inform Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração Limite: Humans / Male Idioma: En Revista: JCO Clin Cancer Inform Ano de publicação: 2023 Tipo de documento: Article